PMID- 36439471
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221129
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Transarterial chemoembolization plus apatinib with or without camrelizumab for 
      unresected hepatocellular carcinoma: A two-center propensity score matching 
      study.
PG  - 1057560
LID - 10.3389/fonc.2022.1057560 [doi]
LID - 1057560
AB  - PURPOSE: To compare the effectiveness and safety of transarterial 
      chemoembolization (TACE) combined with apatinib and camrelizumab with those of 
      TACE as well as apatinib among patients with unresectable hepatocellular 
      carcinoma (HCC). MATERIALS AND METHODS: The data of patients with unresectable 
      HCC (uHCC) who received TACE-apatinib-camrelizumab combination (TACE + AC group) 
      and TACE-apatinib combination (TACE + A group) were collected from two centers 
      between January 2018 and January 2022. Propensity score matching (PSM) was 
      conducted to diminish the bias between the two groups. The primary outcome 
      measures of the study were overall survival (OS) and progression-free survival 
      (PFS), and the secondary outcome measures were response rate (ORR), disease 
      control rate (DCR), and adverse events (AEs). RESULTS: A total of 102 patients 
      were enrolled in this study after PSM, with 34 patients in the TACE + AC group 
      and 68 patients in the TACE + A group. Compared to the TACE + A group, TACE + AC 
      had a significantly longer median OS (25.5 months, interquartile range [IQR], 
      23.5-33.0) than 18.5 months (IQR, 13.0-25.0; P = 0.001). Similarly, the PFS of 
      the TACE + AC group was significantly improved (14.0 months, IQR, 9.0-NA) 
      compared to that of the TACE + A group (5.0 months, IQR, 2.5-9.0; P = 0.001). The 
      ORR rates (55.9% vs. 51.5%), and DCR rates (79.4% vs. 72.1%) were comparable 
      between groups (P > 0.05). All treatment-related adverse events were tolerable 
      and manageable, and no serious adverse events were observed. CONCLUSION: TACE 
      combined with apatinib plus camrelizumab demonstrated superior efficacy to TACE 
      plus apatinib for patients with unresectable HCC. The two combination therapies 
      showed similar safety profiles.
CI  - Copyright (c) 2022 Zhu, Ma, Yang, Zhou, Shi, Ren, Xie, Liu, Shi and Zhou.
FAU - Zhu, Di
AU  - Zhu D
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Nanjing 
      Medical University, Nanjing, China.
FAU - Ma, Kun
AU  - Ma K
AD  - Department of Interventional Radiology, The Affiliated Hospital of Nanjing 
      University of Chinese Medicine, Nanjing, China.
FAU - Yang, Wei
AU  - Yang W
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Nanjing 
      Medical University, Nanjing, China.
FAU - Zhou, Hai-Feng
AU  - Zhou HF
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Nanjing 
      Medical University, Nanjing, China.
FAU - Shi, Qi
AU  - Shi Q
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Nanjing 
      Medical University, Nanjing, China.
FAU - Ren, Jian-Wu
AU  - Ren JW
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Nanjing 
      Medical University, Nanjing, China.
FAU - Xie, Yu-Guan
AU  - Xie YG
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Nanjing 
      Medical University, Nanjing, China.
FAU - Liu, Sheng
AU  - Liu S
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Nanjing 
      Medical University, Nanjing, China.
FAU - Shi, Hai-Bin
AU  - Shi HB
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Nanjing 
      Medical University, Nanjing, China.
FAU - Zhou, Wei-Zhong
AU  - Zhou WZ
AD  - Department of Interventional Radiology, The First Affiliated Hospital of Nanjing 
      Medical University, Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20221110
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9685301
OTO - NOTNLM
OT  - PD-1
OT  - apatinib
OT  - hepatocellular carcinoma
OT  - immunotherapy
OT  - prognosis
OT  - transarterial chemoembolization
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/11/29 06:00
MHDA- 2022/11/29 06:01
PMCR- 2022/01/01
CRDT- 2022/11/28 04:38
PHST- 2022/09/29 00:00 [received]
PHST- 2022/10/24 00:00 [accepted]
PHST- 2022/11/28 04:38 [entrez]
PHST- 2022/11/29 06:00 [pubmed]
PHST- 2022/11/29 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.1057560 [doi]
PST - epublish
SO  - Front Oncol. 2022 Nov 10;12:1057560. doi: 10.3389/fonc.2022.1057560. eCollection 
      2022.